WO2006054862A1 - Method for measuring heptoglobin level in blood serum and kit therefor - Google Patents

Method for measuring heptoglobin level in blood serum and kit therefor Download PDF

Info

Publication number
WO2006054862A1
WO2006054862A1 PCT/KR2005/003882 KR2005003882W WO2006054862A1 WO 2006054862 A1 WO2006054862 A1 WO 2006054862A1 KR 2005003882 W KR2005003882 W KR 2005003882W WO 2006054862 A1 WO2006054862 A1 WO 2006054862A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
heptoglobin
level
blood serum
disease
Prior art date
Application number
PCT/KR2005/003882
Other languages
French (fr)
Inventor
Yu-Sam Kim
Kook-Jin Lim
Original Assignee
Yu-Sam Kim
Kook-Jin Lim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yu-Sam Kim, Kook-Jin Lim filed Critical Yu-Sam Kim
Priority to US11/719,439 priority Critical patent/US20090117597A1/en
Priority to EP05820942A priority patent/EP1812795A4/en
Publication of WO2006054862A1 publication Critical patent/WO2006054862A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a method for measuring heptoglobin level in blood serum and an immunodetection kit therefor, more particularly, to a method for measuring heptoglobin level in blood serum by using antibodies for ⁇ and ⁇ subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for ⁇ and ⁇ subunits of heptoglobin for measuring heptoglobin level in blood serum.
  • Hemoglobin is the most abundant metalloprotein in erythrocyte and plays a crucial role of oxygen-transport in body. Hemoglobin may exert a bad influence upon human body, since iron-containing heme group of the secreted hemoglobin produces a reactive oxygen species harmful to the cells.
  • Hb-Hp hemoblobin-heptoglobin
  • Heptoglobin is a macromolecular glycoprotein in blood serum of mammal, which is composed of two subunits, i.e., ⁇ subunit and ⁇ subunit. The reported molecular weights of the subunits have varied with the ⁇ subunit having been described as 9 and 16.5kDa, and the ⁇ subunit having been described as 4OkDa. Heptoglobin is synthesized as a single chain and separated into N-terminal ⁇ subunit and C-terminal ⁇ subunit. ⁇ subunit and ⁇ subunit are linked by disulfide bond to form a heterodimer. In biological environments such as blood, heptoglobin binds to hemoglobin to form a stable Hb-Hp complex which is degraded by leucocyte.
  • the present inventors have made an effort to develop a method for measuring normal heptoglobin level in blood serum, and discovered that only normal heptoglobin level can be measured to diagnose an attack of diseases which disrupt erythrocytes can be diagnosed in an accurate manner, by using a kit for the immunodetection of heptoglobin comprising antibodies which bind specifically to ⁇ and ⁇ subunits of dimeric heptoglobin, respectively.
  • the first object of the invention is, therefore, to provide a method for measuring normal heptoglobin level in blood serum by using antibodies which bind specifically to ⁇ and ⁇ subunits of heptoglobin.
  • the second object of the invention is to provide a method for diagnosing an attack of diseases which disrupt erythrocytes by using antibodies which bind specifically to ⁇ and ⁇ subunits of heptoglobin.
  • the third object of the invention is to provide a kit for immunodetection of heptoglobin which measures heptoglobin level in blood serum.
  • the fourth object of the invention is to provide a method for diagnosing an attack of diseases which disrupt erythrocytes by using the kit for immunodetection of heptoglobin. [16]
  • Figure 1 is a photograph showing an electrophoresis pattern of proteins in blood serum from a normal.
  • Figure 2 is a photograph showing an electrophoresis pattern of proteins in blood serum from a malaria patient.
  • the present inventors performed 2D-electrophoresis for the blood sera from a normal and a malaria patient and compared protein patterns with each other, which revealed that hemoglobin level increased but heptoglobin level decreased in blood serum of a malaria patient. They also measured heptoglobin levels in blood sera from a normal and a malaria patient by using antibodies which bind specifically to ⁇ and ⁇ subunits of heptoglobin, respectively, and by using an antibody for heptoglobin, and comparison of them with each other was followed.
  • a method for measuring heptoglobin level in blood serum of the present invention comprises the steps of: (i) reacting blood serum of a subject with an antibody ( ⁇ h antibody) which binds specifically to ⁇ subunit of a dimeric heptoglobin and an antibody( ⁇ h antibody) which binds specifically to ⁇ subunit of a dimeric heptoglobin; and, (ii) measuring level of proteins which react with the ⁇ h antibody and ⁇ h antibody in blood serum and have a molecular weight of more than 10OkDa.
  • the level of proteins is preferably measured by Western blot analysis or Sandwich ELISA method using a pair of antibodies: a non-labled ⁇ h antibody and a labled ⁇ h antibody; or, a labled ⁇ h antibody and a non-labled ⁇ h antibody.
  • the labling of antibody is done by: fluorescent materials such as Cy-3, Cy-5, FITC(fluorescein isothiocyanate), GFP(green fluorescent protein), RFP(red fluorescent protein) or Texas Red; radioisotopes such as H, C or P; or, enzymes such as HRP(horse raddish peroxidase), alkaline phosphatase, ⁇ -galactosidase or luciferase.
  • fluorescent materials such as Cy-3, Cy-5, FITC(fluorescein isothiocyanate), GFP(green fluorescent protein), RFP(red fluorescent protein) or Texas Red
  • radioisotopes such as H, C or P
  • enzymes such as HRP(horse raddish peroxidase), alkaline phosphatase, ⁇ -galactosidase or luciferase.
  • the present inventors demonstrated that an attack of disease such as a malaria which disrupts erythrocyte can be diagnosed by measuring the normal heptoglobin level in blood serum which employs antibodies which bind specifically to ⁇ and ⁇ subunits of heptoglobin, respectively, or by using a kit for immunodetection of heptoglobin containing the said antibodies.
  • the present invention provides a method for diagnosing an attack of disease which disrupts erythrocyte, which comprises the steps of: (i) reacting blood serum of a subject with an antibody ( ⁇ h antibody) which binds specifically to ⁇ subunit of a dimeric heptoglobin and an antibody( ⁇ h antibody) which binds specifically to ⁇ subunit of a dimeric heptoglobin; (ii) measuring level of proteins which react with the ⁇ h antibody and ⁇ h antibody in blood serum and have a molecular weight of more than 10OkDa; and, comparing the measured protein level with protein level of a normal, where the level of proteins is measured in a similar manner as described above.
  • the present invention provides a kit for immunodetection of heptoglobin containing antibodies which bind specifically to ⁇ and ⁇ subunits of a dimeric heptoglobin, respectively, which comprises: (i) a plate on which an antibody which binds specifically to ⁇ subunit or ⁇ subunit of heptoglobin is fixed; (ii) a solution containing an antibody which binds specifically to ⁇ subunit or ⁇ subunit which is not bound to the antibody fixed on the plate; (iii) a secondary antibody which binds to the antibody in the solution; and, (iv) a means for detecting the secondary antibody.
  • the plate is preferably glass or plastic
  • the secondary antibody not limited thereto, is preferably labeled with biotin- or peroxidase-labeled rabbit-goat serum
  • the means for detecting the secondary antibody is preferably hydrogen peroxide or streptavidin.
  • the present invention provides a method for diagnosing an attack of disease such as a malaria which disrupts erythrocyte by measuring dimeric heptoglobin level by using the kit for immunodetection of heptoglobin.
  • the method for diagnosing an attack of disease which disrupts erythrocyte comprises the steps of: (i) collecting blood sera from a normal and a subject who is doubted as a patient suffering from a disease which disrupts erythrocyte; (ii) adding each of the collected sera to a plate in the said kit to react with an antibody fixed on the plate; (iii) removing the serum from the plate and adding a solution containing an antibody in the said kit to the plate; (iv) removing the solution from the plate and adding a secondary antibody in the said kit; (v) removing the secondary antibody from the plate and adding a means for detecting the secondary antibody in the said kit to measure levels of heptoglobin; and, (vi) comparing the levels of heptoglobin with each other
  • Example 1 Comparison of levels of proteins in blood sera from a normal and a malaria patient
  • FIGS. 1 and 2 are photographs showing an electrophoresis pattern of proteins in blood sera from a normal and a malaria patient, respectively. As shown in Figures 1 and 2, it was demostrated that proteins in blood serum from a malaria patient in Areas 1 and 2 were significantly decreased, whereas proteins in Areas 3 and 4 were sig ⁇ nificantly increased.
  • Example 2 Preparation of a kit for immunodetection of heptoglobin
  • Antibodies for ⁇ and ⁇ subunits of heptoglobin were prepared, respectively, and employed to prepare a kit for immunodetection of heptoglobin as follows.
  • Example 2-1 Preparation of antibodies for ⁇ and ⁇ subunits of heptoglobin
  • the blood serum was applied on a gel filtration chromatography which is capable of separating proteins in a range of molecular weight determined as above, fractions were collected and subjected to Western blotting to identify fractions containing an antibody for ⁇ subunit of heptoglobin.
  • An antibody for ⁇ subunit of heptoglobin was also prepared similarly as the above except for using ⁇ subunit instead of ⁇ subunit.
  • Example 2-2 Preparation of a kit for immunodetection of heptoglobin
  • a glass plate on which an antibody for ⁇ subunit of heptoglobin is fixed, Tris buffer solution(50 mM Tris/HCl, pH 8.0) containing an antibody for ⁇ subunit of heptoglobin and 50% glycerol, peroxidase-labeled rabbit-goat serum(a secondary antibody) and hydrogen peroxide were prepared, respectively, to manufacture a kit for immun ⁇ odetection of heptoglobin.
  • Example 3 Comparison of heptoglobin levels in blood sera from a normal and a malaria patient by using a kit for immunodetection of heptoglobin
  • Example 2 To a plate of an immunodetection kit for heptoglobin prepared in Example 2 was added each of blood sera collected from a normal and a malaria patient prepared in Example 1, respectively, incubated for 2 hours at room temperature, removed the blood serum from the plate, and washed with PBS. Then, to the plate was added a solution containing an antibody which binds specifically to ⁇ or ⁇ subunit of heptoglobin, incubated for 2 hours at room temperature, removed the solution from the plate, and washed with PBS again. And then, peroxidase-labeled rabbit-goat serum of the kit was added to the plate, reacted for 30 min at room temperature, added hydrogen peroxide, and measurement of absorbance was followed in ELISA reader.
  • the present invention provides a method for measuring heptoglobin level in blood serum by using antibodies for ⁇ and ⁇ subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for ⁇ and ⁇ subunits of heptoglobin for measuring heptoglobin level in blood serum.
  • the method for measuring heptoglobin level in blood serum can be practically applied for the early diagnosis of dieases which disrupt erythrocytes, since only the level of normal heptoglobin except for monomeric and degraded heptoglobins can be specifically measured by the said method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a method for measuring heptoglobin level in blood serum by using antibodies for α and β subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for α and β subunits of heptoglobin for measuring heptoglobin level in blood serum. A method for measuring heptoglobin level in blood serum of the present invention comprises the steps of: reacting blood serum of a subject with an antibody(αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody(βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; and, measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 100kDa. The method for measuring heptoglobin level in blood serum can be practically applied for the early diagnosis of dieases which disrupt erythrocytes, since only the level of normal heptoglobin except for monomelic and degraded hep- toglobins can be specifically measured by the said method.

Description

Description
METHOD FOR MEASURING HEPTOGLOBIN LEVEL IN BLOOD SERUM AND KIT THEREFOR
Technical Field
[1] The present invention relates to a method for measuring heptoglobin level in blood serum and an immunodetection kit therefor, more particularly, to a method for measuring heptoglobin level in blood serum by using antibodies for α and β subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for α and β subunits of heptoglobin for measuring heptoglobin level in blood serum.
[2]
Background Art
[3] In normal cases, erythrocytes become senescent after 120 days, and degraded in bone marrow, liver and pancreas. However, rupture of erythrocytes owing to an attack of malaria or autoimmune disease frequently lead to the secretion of hemoglobin into blood. Hemoglobin is the most abundant metalloprotein in erythrocyte and plays a crucial role of oxygen-transport in body. Hemoglobin may exert a bad influence upon human body, since iron-containing heme group of the secreted hemoglobin produces a reactive oxygen species harmful to the cells. When hemoglobin is secreted abnormally as described, the secreted hemoglobin is degraded by leucocyte in a form of hemoblobin-heptoglobin(Hb-Hp) complex.
[4] Heptoglobin is a macromolecular glycoprotein in blood serum of mammal, which is composed of two subunits, i.e., α subunit and β subunit. The reported molecular weights of the subunits have varied with the α subunit having been described as 9 and 16.5kDa, and the β subunit having been described as 4OkDa. Heptoglobin is synthesized as a single chain and separated into N-terminal α subunit and C-terminal β subunit. α subunit and β subunit are linked by disulfide bond to form a heterodimer. In biological environments such as blood, heptoglobin binds to hemoglobin to form a stable Hb-Hp complex which is degraded by leucocyte.
[5] When erythrocytes are disrupted in blood by a disease such as malaria, hemoglobins are secreted into blood serum and bound to heptoglobin, and forms Hb-Hp complex which is degraded by leucocyte. Thus, continuous disruption of erythrocytes may lead to decrease in heptoglobin level in blood serum. For the diagnosis of malaria, whose external symptom at an early stage of infection is not shown, a method for examining blood from a patient has been used for a while. But, a method of counting the numbers of erythrocytes has come into wide use presently, since the secreted hemoglobin is degraded rapidly. The method for counting the numbers of erythrocytes in human blood is, however, proven to be less satisfactory in a sense that it has a wide range of errors, and does not distinguish a normal from a malaria patient accurately.
[6] As an approach of overcoming the said problem, a method for counting the numbers of heptoglobin in blood serum has been practiced for the diagnosis and prognosis of diseases which disrupt erythrocytes, based on experimental reports that heptoglobin level in blood serum from a malaria patient is lower than a normal.
[7] Nevertheless, since heptoglobin level in blood serum has been measured by using polyclonal antibody, the prior art method reveals a shortcoming that it detects monomer, dimer, and degraded fragments as well, leading to a wide range of errors than the method of counting the numbers of erythrocytes, therefore, it is no more used in the art. If normal heptoglobin level in blood serum can be measured specifically, the diagnosis of diseases which disrupt erythrocytes would be made in an accurate manner.
[8] Under the circumstances, there are strong reasons for exploring and developing a method for measuring normal heptoglobin level in blood serum.
[9]
Disclosure of Invention Technical Problem
[10] The present inventors have made an effort to develop a method for measuring normal heptoglobin level in blood serum, and discovered that only normal heptoglobin level can be measured to diagnose an attack of diseases which disrupt erythrocytes can be diagnosed in an accurate manner, by using a kit for the immunodetection of heptoglobin comprising antibodies which bind specifically to α and β subunits of dimeric heptoglobin, respectively.
[H]
Technical Solution
[12] The first object of the invention is, therefore, to provide a method for measuring normal heptoglobin level in blood serum by using antibodies which bind specifically to α and β subunits of heptoglobin. [13] The second object of the invention is to provide a method for diagnosing an attack of diseases which disrupt erythrocytes by using antibodies which bind specifically to α and β subunits of heptoglobin. [14] The third object of the invention is to provide a kit for immunodetection of heptoglobin which measures heptoglobin level in blood serum. [15] The fourth object of the invention is to provide a method for diagnosing an attack of diseases which disrupt erythrocytes by using the kit for immunodetection of heptoglobin. [16]
Brief Description of the Drawings
[17] The above and the other objects and features of the present invention will become apparent from the following descriptions given in conjunction with the accompanying drawings, in which:
[18] Figure 1 is a photograph showing an electrophoresis pattern of proteins in blood serum from a normal.
[19] Figure 2 is a photograph showing an electrophoresis pattern of proteins in blood serum from a malaria patient.
[20]
Best Mode for Carrying Out the Invention
[21] The present inventors performed 2D-electrophoresis for the blood sera from a normal and a malaria patient and compared protein patterns with each other, which revealed that hemoglobin level increased but heptoglobin level decreased in blood serum of a malaria patient. They also measured heptoglobin levels in blood sera from a normal and a malaria patient by using antibodies which bind specifically to α and β subunits of heptoglobin, respectively, and by using an antibody for heptoglobin, and comparison of them with each other was followed. As a result, they found that the levels of dimeric, monomeric and degraded heptoglobins were totally measured by using the antibody for a dimeric heptoglobin, whereas only the level of normal heptoglobin was measured by using the antibodies for α and β subunits of heptoglobin, implying that the level of dimeric heptoglobin can be measured specifically by using antibodies which bind specifically to α and β subunits of heptoglobin, respectively.
[22] A method for measuring heptoglobin level in blood serum of the present invention comprises the steps of: (i) reacting blood serum of a subject with an antibody (αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody(βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; and, (ii) measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 10OkDa. The level of proteins, not limited thereto, is preferably measured by Western blot analysis or Sandwich ELISA method using a pair of antibodies: a non-labled αh antibody and a labled βh antibody; or, a labled αh antibody and a non-labled βh antibody. The labling of antibody is done by: fluorescent materials such as Cy-3, Cy-5, FITC(fluorescein isothiocyanate), GFP(green fluorescent protein), RFP(red fluorescent protein) or Texas Red; radioisotopes such as H, C or P; or, enzymes such as HRP(horse raddish peroxidase), alkaline phosphatase, β-galactosidase or luciferase.
[23] According to the method for measuring normal heptoglobin level in blood serum, the present inventors demonstrated that an attack of disease such as a malaria which disrupts erythrocyte can be diagnosed by measuring the normal heptoglobin level in blood serum which employs antibodies which bind specifically to α and β subunits of heptoglobin, respectively, or by using a kit for immunodetection of heptoglobin containing the said antibodies.
[24] The present invention provides a method for diagnosing an attack of disease which disrupts erythrocyte, which comprises the steps of: (i) reacting blood serum of a subject with an antibody (αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody(βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; (ii) measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 10OkDa; and, comparing the measured protein level with protein level of a normal, where the level of proteins is measured in a similar manner as described above.
[25] Further, the present invention provides a kit for immunodetection of heptoglobin containing antibodies which bind specifically to α and β subunits of a dimeric heptoglobin, respectively, which comprises: (i) a plate on which an antibody which binds specifically to α subunit or β subunit of heptoglobin is fixed; (ii) a solution containing an antibody which binds specifically to α subunit or β subunit which is not bound to the antibody fixed on the plate; (iii) a secondary antibody which binds to the antibody in the solution; and, (iv) a means for detecting the secondary antibody. The plate, not limited thereto, is preferably glass or plastic, the secondary antibody, not limited thereto, is preferably labeled with biotin- or peroxidase-labeled rabbit-goat serum, and the means for detecting the secondary antibody, not limited thereto, is preferably hydrogen peroxide or streptavidin.
[26] Finally, the present invention provides a method for diagnosing an attack of disease such as a malaria which disrupts erythrocyte by measuring dimeric heptoglobin level by using the kit for immunodetection of heptoglobin. The method for diagnosing an attack of disease which disrupts erythrocyte comprises the steps of: (i) collecting blood sera from a normal and a subject who is doubted as a patient suffering from a disease which disrupts erythrocyte; (ii) adding each of the collected sera to a plate in the said kit to react with an antibody fixed on the plate; (iii) removing the serum from the plate and adding a solution containing an antibody in the said kit to the plate; (iv) removing the solution from the plate and adding a secondary antibody in the said kit; (v) removing the secondary antibody from the plate and adding a means for detecting the secondary antibody in the said kit to measure levels of heptoglobin; and, (vi) comparing the levels of heptoglobin with each other. The secondary antibody and means for detecting the secondary antibody are the same as described above.
[27] Mode for the Invention
[28] The present invention is further illustrated in the following examples, which should not be taken to limit the scope of the invention.
[29]
[30] Example 1 : Comparison of levels of proteins in blood sera from a normal and a malaria patient
[31]
[32] 2D-electrophoresis for the blood sera from a normal and a malaria patient was performed as follows. Blood serum was collected from a normal and a malaria patient, respectively, and blood serum containing 150 D of serum proteins was mixed with 50 D of SDS/DTT solubilization buffer(0.3% SDS, 3% DTT(dithiothreitol), 50 mM Tris/ HCl, pH 8.0), and incubated at 95°C for 5 min. Then, 500 D of enhanced solubilising solution(7 M urea, 2 M thiourea, 4%
CHAPS(3-[(3-cholamidopropyl)dimethylammonio]-l-propan-sulfonate), 40 mM Tris/ HCl, 0.002% bromophenol blue, 2 mM tributylphospine) was added and centrifuged at 17,000 rpm for 15 min, at 4°C to obtain a supernatant. And then, 500 D of the su¬ pernatant was loaded on immobiline pH gradient(IPG) dry strip tray and the IPG dry strip(pH 3-10, 18 D) was rehydrated for 16 hours. IEF(isoelectric focusing) of the rehydrated strip was performed by applying a voltage of 100 kVh in Multiphor apparatus(Amersham-Pharmacia Biotech, Sweden) to move serum proteins to isoelectric point(PI).
[33] 90 ml of 5X Tris/HCl(l .875 M, pH 8.8), 90 ml of 40% acrylamide solution, 4.5 ml of 10% SDS, 90 D of 100 mM sodium thiosulfate, 740 D of 10% ammonium persulfate, 74 D of TEMED and 270 ml of distilled water were mixed to prepare 8% poly- acrylamide gradient gel solution, and 90 ml of 5X Tris/HCl( 1.875 M, pH 8.8), 180 ml of 40% acrylamide solution, 90 ml of 50% glycerol, 4.5 ml of 10% SDS, 90 D of 100 mM sodium thiosulfide, 740 D of 10% ammonium persulfate, 74 D of TEMED and 90 ml of distilled water were mixed to prepare 16% polyacrylamide gradient gel solution. Then, 8 to 16% gradient gel SDS-PAGE(18 cm width X 1.5 mm height) was prepared by using the polyacrylamide gel solutions prepared as above.
[34] To the IEF performed strip was added 10 ml of TBP equilibrium buffer solution(0.2 mM tributyl phosphine, 6 M urea, 2% SDS, 375 mM Tris buffer(pH 8.8), 20% glycerol and 2.5% acrylamide), and shaked slightly for 15 min to reach an equilibrium state. The equilibrated strip was loaded on the SDS-PAGE gel prepared as above, and poured agarose embedding solution(agarose, 1% bromophenol blue, IX SDS running buffer) up to the glass top to fix the strip on the gel. The strip on 8-16% gradient gel was put into a bottle containing SDS-PAGE running buffer(glycine, SDS and Tris-base), and electrophoresed in 200 mA for 12 hours. Then, gel was stained to compare protein level of blood serum from a normal with that from a malaria patientfsee: Figures 1 and 2). Figures 1 and 2 are photographs showing an electrophoresis pattern of proteins in blood sera from a normal and a malaria patient, respectively. As shown in Figures 1 and 2, it was demostrated that proteins in blood serum from a malaria patient in Areas 1 and 2 were significantly decreased, whereas proteins in Areas 3 and 4 were sig¬ nificantly increased.
[35] Proteins from each area were isolated and treated with trypsin, and subjected to
MALDI-TOF analysis, which revealed that all proteins in Areas 1 and 2 were identified as heptoglobin, proteins in Areas 3 and 4 were identified as hemoglobin, re¬ spectively. Accordingly, it was clearly demostrated that heptoglobin level in blood serum from a malaria patient is lower than that of a normal.
[36]
[37] Example 2: Preparation of a kit for immunodetection of heptoglobin
[38]
[39] Antibodies for α and β subunits of heptoglobin were prepared, respectively, and employed to prepare a kit for immunodetection of heptoglobin as follows.
[40]
[41] Example 2-1: Preparation of antibodies for α and β subunits of heptoglobin
[42]
[43] A mixture of 2 ml of α subunit of heptoglobin and 2 ml of adjuvant was injected into 7 weeks old rabbit three times at an interval of 1 week and two times at an interval of 2 weeks. Then, small amount of blood was collected from the immunized rabbit and measured titer of an antibody for α subunit, and whole blood was collected from the immunized rabbit by cardiac puncture. The blood thus collected was left to stand for 1 day at room temperature to obtain blood serum as a supernatant. And then, the blood serum was electrophoresed on 12%(v/v) acrylamide gradient gel, and subjected to Western blot analysis using α subunit to determine molecular weight of antibodies in blood serum.
[44] Then, the blood serum was applied on a gel filtration chromatography which is capable of separating proteins in a range of molecular weight determined as above, fractions were collected and subjected to Western blotting to identify fractions containing an antibody for α subunit of heptoglobin. An antibody for β subunit of heptoglobin was also prepared similarly as the above except for using β subunit instead of α subunit.
[45]
[46] Example 2-2: Preparation of a kit for immunodetection of heptoglobin
[47] [48] A glass plate on which an antibody for α subunit of heptoglobin is fixed, Tris buffer solution(50 mM Tris/HCl, pH 8.0) containing an antibody for β subunit of heptoglobin and 50% glycerol, peroxidase-labeled rabbit-goat serum(a secondary antibody) and hydrogen peroxide were prepared, respectively, to manufacture a kit for immun¬ odetection of heptoglobin.
[49]
[50] Example 3: Comparison of heptoglobin levels in blood sera from a normal and a malaria patient by using a kit for immunodetection of heptoglobin
[51]
[52] To a plate of an immunodetection kit for heptoglobin prepared in Example 2 was added each of blood sera collected from a normal and a malaria patient prepared in Example 1, respectively, incubated for 2 hours at room temperature, removed the blood serum from the plate, and washed with PBS. Then, to the plate was added a solution containing an antibody which binds specifically to α or β subunit of heptoglobin, incubated for 2 hours at room temperature, removed the solution from the plate, and washed with PBS again. And then, peroxidase-labeled rabbit-goat serum of the kit was added to the plate, reacted for 30 min at room temperature, added hydrogen peroxide, and measurement of absorbance was followed in ELISA reader.
[53]
[54] Comparative Example: Comparison of heptoglobin levels in blood sera from a normal and a malaria patient by using an antibody for heptoglobin
[55]
[56] Measurement of heptoglobin level in blood sera was performed by using an antibody for dimeric heptoglobin, not antibodies for α and β subunits of heptoglobin: An antibody for heptoglobin was prepared in a similar manner as in Example 2-1 except for using a dimeric heptoglobin instead of α subunit. Then, a glass plate on which an antibody for dimeric heptoglobin is fixed, Tris buffer solution(50 mM Tris/ HCl, pH 8.0) containing an antibody for dimeric heptoglobin and 50% glycerol, peroxidase-labeled rabbit-goat serum(a secondary antibody) and hydrogen peroxide were prepared, respectively, to manufacture a kit for immunodetection of dimeric heptoglobin. And then, absorbance measurement for blood sera from a normal and a malaria patient was followed in a similar manner as in Example 3, except for using a kit for immunodetection of dimeric heptoglobin, and compared with the results of Example 3(see: Table 1)
[57]
[58] Table 1
Comparison of the heptoglobin levels in blood sera from a normal and a malaria patient(unit: absorbance)
Figure imgf000009_0001
[59]
[60] As can be seen in Table 1 above, it was found that haptoglobin level measured by using a kit of heptoglobin comprising antibodies for α and β subunits of heptoglobin(Example 3) is lower than that measured by using a kit comprising an antibody for dimeric heptoglobin(Comparative Example), implying that the levels of dimeric, monomeric and degraded heptoglobins were totally measured by using the antibody for dimeric heptoglobin(Comparative Example), whereas only the level of normal heptoglobin was measured by using the antibodies for α and β subunits of heptoglobin(Example 3). Therefore, it was clearly demonstrated that the level of heptoglobin in blood serum can be measured accurately by employing an immun¬ odetection kit for heptoglobin of present invention.
[61]
Industrial Applicability [62] As clearly explained and demonstrated as the above, the present invention provides a method for measuring heptoglobin level in blood serum by using antibodies for α and β subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for α and β subunits of heptoglobin for measuring heptoglobin level in blood serum. The method for measuring heptoglobin level in blood serum can be practically applied for the early diagnosis of dieases which disrupt erythrocytes, since only the level of normal heptoglobin except for monomeric and degraded heptoglobins can be specifically measured by the said method.
[63] [64]

Claims

Claims
[1] A method for measuring heptoglobin level in blood serum, which comprises the steps of:
(i) reacting blood serum of a subject with an antibody (αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody(βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; and, (ii) measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 10OkDa.
[2] The method for measuring heptoglobin level in blood serum of claim 1, wherein the level of proteins is measured by Western blot analysis.
[3] The method for measuring heptoglobin level in blood serum of claim 1, wherein the level of proteins is measured by Sandwich ELISA method.
[4] The method for measuring heptoglobin level in blood serum of claim 3, wherein the level of proteins is measured by using a labled αh antibody and a non-labled βh antibody.
[5] The method for measuring heptoglobin level in blood serum of claim 3, wherein the level of proteins is measured by using a non-labled αh antibody and a labled βh antibody.
[6] The method for measuring heptoglobin level in blood serum of claim 4 or 5, wherein the labling of antibody is done by fluorescent material, radioisotope or enzyme.
[7] The method for measuring heptoglobin level in blood serum of claim 6, wherein the fluorescent material is Cy-3, Cy-5, FITC(fluorescein isothiocyanate), GFP(green fluorescent protein), RFP(red fluorescent protein) or Texas Red.
[8] The method for measuring heptoglobin level in blood serum of claim 6, wherein the enzyme is HRP(horse raddish peroxidase), alkaline phosphatase, β- galactosidase or luciferase.
[9] A method for diagnosing an attack of disease which disrupts erythrocyte, which comprises the steps of:
(i) reacting blood serum of a subject with an antibody (αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody(βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; (ii) measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 10OkDa; and, (iii) comparing the measured protein level with protein level of a normal.
[10] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 9, wherein the level of proteins is measured by Western blot analysis. [11] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 9, wherein the level of proteins is measured by Sandwich ELISA method. [12] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 11, wherein the level of proteins is measured by using a labled αh antibody and a non-labled βh antibody. [13] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 11, wherein the level of proteins is measured by using a non-labled αh antibody and a labled βh antibody. [14] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 12 or 13, wherein the labling of antibody is done by fluorescent material, radioisotope or enzyme. [15] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 14, wherein the fluorescent material is Cy-3, Cy-5, FITC(fluorescein isoth- iocyanate), GFP(green fluorescent protein), RFP(red fluorescent protein) or
Texas Red. [16] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 14, wherein the enzyme is HRP(horse raddish peroxidase), alkaline phosphatase, β-galactosidase or luciferase. [17] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 9, wherein the disease is malaria. [18] A kit for immunodetection of heptoglobin which comprises:
(i) a plate on which an antibody which binds specifically to α subunit or β subunit of heptoglobin is fixed;
(ii) a solution containing an antibody which binds specifically to α subunit or β subunit which is not bound to the antibody on the plate;
(iii) a secondary antibody which binds to the antibody in the solution; and,
(iv) a means for detecting the secondary antibody. [19] The kit for immunodetection of heptoglobin of claim 18, wherein the plate is glass or plastic. [20] The kit for immunodetection of heptoglobin of claim 18, wherein the secondary antibody is labeled with biotin- or peroxidase-labeled rabbit-goat serum. [21] The kit for immunodetection of heptoglobin of claim 18, wherein the means for detecting the secondary antibody is hydrogen peroxide or streptavidin. [22] A method for diagnosing an attack of disease which disrupts erythrocyte by using a kit for immunodetection of heptoglobin of claim 18, which comprises the steps of:
(i) collecting blood sera from a normal and a subject who is doubted as a patient suffering from a disease which disrupts erythrocyte; (ii) adding each of the collected sera to a plate in the said kit to react with an antibody fixed on the plate;
(iii) removing the serum from the plate and adding a solution containing an antibody in the said kit to the plate;
(iv) removing the solution from the plate and adding a secondary antibody in the said kit;
(v) removing the secondary antibody from the plate and adding a means for detecting the secondary antibody in the said kit to measure levels of heptoglobin; and,
(vi) comparing the levels of dimeric heptoglobin with each other. [23] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 22, wherein the disease is malaria. [24] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 22, wherein the secondary antibody is labeled with biotin- or peroxidase- labeled rabbit-goat serum. [25] The method for diagnosing an attack of disease which disrupts erythrocyte of claim 22, wherein the means for detecting the secondary antibody is hydrogen peroxide or streptavidin. [26] A kit for diagnosing malaria, which comprises:
(i) a plate on which an antibody which binds specifically to α subunit or β subunit of heptoglobin is fixed;
(ii) a solution containing an antibody which binds specifically to α subunit or β subunit which is not bound to the antibody fixed on the plate;
(iii) biotin- or peroxidase-labeled secondary antibody which binds to the antibody in the solution; and,
(iv) hydrogen peroxide or streptavidin for detecting the secondary antibody.
PCT/KR2005/003882 2004-11-16 2005-11-16 Method for measuring heptoglobin level in blood serum and kit therefor WO2006054862A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/719,439 US20090117597A1 (en) 2004-11-16 2005-11-16 Method for Measuring Heptoglobin Level in Blood Serum and Kit Therefor
EP05820942A EP1812795A4 (en) 2004-11-16 2005-11-16 Method for measuring heptoglobin level in blood serum and kit therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2004-0093348 2004-11-16
KR1020040093348A KR101050385B1 (en) 2004-11-16 2004-11-16 Heptoglobin immune detection kit

Publications (1)

Publication Number Publication Date
WO2006054862A1 true WO2006054862A1 (en) 2006-05-26

Family

ID=36407373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/003882 WO2006054862A1 (en) 2004-11-16 2005-11-16 Method for measuring heptoglobin level in blood serum and kit therefor

Country Status (4)

Country Link
US (1) US20090117597A1 (en)
EP (1) EP1812795A4 (en)
KR (1) KR101050385B1 (en)
WO (1) WO2006054862A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946774A (en) * 1987-11-09 1990-08-07 Trustees Of Boston University Process for detecting cancer and for monitoring the effectiveness of cancer therapy
US5552295A (en) * 1994-03-02 1996-09-03 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to bovine haptoglobin and methods for detecting serum haptoglobin levels
WO2002100242A2 (en) * 2001-06-08 2002-12-19 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723773D0 (en) 1997-11-12 1998-01-07 Univ Glasgow Haptoglobin assay

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946774A (en) * 1987-11-09 1990-08-07 Trustees Of Boston University Process for detecting cancer and for monitoring the effectiveness of cancer therapy
US5552295A (en) * 1994-03-02 1996-09-03 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to bovine haptoglobin and methods for detecting serum haptoglobin levels
WO2002100242A2 (en) * 2001-06-08 2002-12-19 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1812795A4 *
TSENG C F ET AL: "Purification of Human Haptoglobin 1-1, 2-1, and 2-2 Using Monoclonal Antibody Affinity Chromatography.", PROTEIN EXPRESSION & PURIFICATION., vol. 33, no. 2, February 2004 (2004-02-01), XP004482979, DOI: doi:10.1016/j.pep.2003.09.006 *

Also Published As

Publication number Publication date
KR101050385B1 (en) 2011-09-01
EP1812795A1 (en) 2007-08-01
EP1812795A4 (en) 2008-10-08
KR20060054699A (en) 2006-05-23
US20090117597A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
Sutton et al. Detection of IgE-and IgG-binding proteins after electrophoretic transfer from polyacrylamide gels
EP0961780B1 (en) Protein markers for lung cancer and use thereof
Walker et al. A rapid method for detecting oligoclonal IgG in unconcentrated CSF, by agarose isoelectric focusing, transfer to cellulose nitrate and immunoperoxidase staining
Stulík et al. Identification of new celiac disease autoantigens using proteomic analysis
Palosuo et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay
Tamamoto et al. Verification of measurement of the feline serum amyloid A (SAA) concentration by human SAA turbidimetric immunoassay and its clinical application
JP4471867B2 (en) Reference material for D-dimer measurement
Lee et al. Decreased serum group‐specific component protein levels and complexes with actin in fulminant hepatic necrosis
EP1554587A2 (en) Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage
DE60333471D1 (en) POLYCLONAL MONOKLONAL ELISA ASSAY FOR DETECTION OF N-TERMINAL PROBNP
WO2008092214A1 (en) Biomarkers for diabetes
Wenzel et al. Difference between beta1-adrenoceptor autoantibodies of human and animal origin—limitations detecting beta1-adrenoceptor autoantibodies using peptide based ELISA technology
Robinson et al. Identification and characterization of a human corticosteroid binding globulin variant with a reduced affinity for cortisol
Kshirsagar et al. A map of urine proteins based on one-dimensional SDS-polyacrylamide gel electrophoresis and Western blotting using one microliter of unconcentrated urine
WO2006054862A1 (en) Method for measuring heptoglobin level in blood serum and kit therefor
JPH04248465A (en) Immuno-sedimentation method for measuring connectable analite, and reagent for executing said method
Heegaard et al. Comparison of heparin‐binding to lactoferrin from human milk and from human granulocytes by means of affinity capillary electrophoresis
JP2020056621A (en) Method of quantifying liver fatty acid-binding protein, quantification kit for the same, method of testing for renal disease, test kit for the same, and companion diagnostic agent
Norsworthy et al. Complement components and their autoantibodies
US8697368B2 (en) Diagnostic marker for lung cancer comprising HPαR as active ingredient
Ingerslev et al. Diagnosis of von Willebrand disease
Cline et al. Identification of alpha1-lipoproteins in crossed immunoelectrophoresis.
KR101257307B1 (en) Marker proteins for the diagnosis, therapy and monitoring of Atopic dermatitis from human plasma
Li-Min et al. A monoclonal antibody which can distinguish between the two isotypes of human C4
JPH05302922A (en) Diagnosing method for kidney disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005820942

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005820942

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11719439

Country of ref document: US